Anti IL-18 (GSK1070806) in Behcet's Disease
An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Rona M Smith, MD MRCP
- Phone Number: 00441223217259
- Email: rona.smith@addenbrookes.nhs.uk
Study Locations
-
-
-
Cambridge, United Kingdom, CB20QQ
- Addenbrooke's Hospital, University of Cambridge NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have given written informed consent to participate
- Be aged 18 years and over
- Have a diagnosis of Behcet's disease (according to the International Study Group (ISG) diagnostic guidelines or International Criteria for BD (ICBD)).
- Have active disease, severe enough to necessitate the use of biological therapy at the time of enrolment (i.e. Subjects have refractory disease as defined by the UK Centres of Excellence criteria as failure to respond to steroid and/or immunosuppressive therapy with significant or major organ-threatening disease.
Exclusion Criteria:
- Age under 18 years
- Allergies to humanized monoclonal antibodies
Subjects who have received any of the following agents within 364 days of day 0:
- Alemtuzumab
- Rituximab or any other B cell depleting or modulating biological agent
Subjects who have received any of the following agents within 180 days of day 0:
- Cyclophosphamide
- Anti-thymocyte globulin
Subjects who have received any of the following agents within 90 days of Day 0:
- Intravenous immunoglobulin (IVIG)
- Plasmapheresis
Subjects who have received any of the following agents within 30 days of Day 0:
- Anti-TNF (e.g. adalimumab, etanercept, infliximab)
- Anti-IL-6 therapy (e.g. tocilizumab)
- Interleukin-1 receptor antagonist (e.g. anakinra)
- Alpha interferon
- Any live vaccine
- Subjects who have received any other investigational product within 30 days, 5 half lives or twice the duration of the biological effect, whichever is longer.
- Subjects required more than 15mg prednisolone daily in the 4 week run in phase.
- Positive human immunodeficiency virus (HIV) antibody test
- Positive serology for Hepatitis B (HB), defined as: (i) HB surface antigen positive (HBsAg+) OR (ii) HB core antibody positive (HBcAb+)
- Positive Hepatitis C (HCV) antibody test
- Evidence of active or latent tuberculosis (TB) as documented by medical history and examination, chest X-rays (posterior anterior and lateral), and a positive (not indeterminate) QuantiFERON®-TB Gold test.
- Evidence of chronic infection requiring long term antimicrobial therapy
- Serum IgG level < 3g/l
- Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, and carcinoma in situ of the uterine cervix.
- QTc interval (single or average) > 480msec or in subjects with bundle branch block QTc > 500msec (these criteria do not apply to subjects with predominantly paced rhythm).
- Liver function: ALT > 2xULN and bilirubin > 1.5 ULN (isolated bilirubin > 1.5 ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%)
- Compliance: is unlikely to comply with scheduled study visits based on investigator judgment or has a history of substance abuse, psychiatric disorder or condition that may compromise communication with the investigator
- Women who are pregnant or breast feeding
- Women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for one month before and 12 months after administration of GSK1070806
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The occurrence of all moderate, severe and life threatening adverse events
Time Frame: 24 weeks
|
Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)
|
24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All adverse events, including mild events
Time Frame: 24 weeks
|
Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)
|
24 weeks
|
|
Measurement of disease activity
Time Frame: 24 weeks
|
Using a clinical scoring tool, the Behcet's disease current activity form (BDCAF)
|
24 weeks
|
|
Measurement of the accumulation of damage
Time Frame: 24 weeks
|
Using a clinical scoring tool, the Vasculitis Damage Index (VDI)
|
24 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of serum free IL-18 and total IL-18 levels
Time Frame: 6 weeks
|
Pre and post GSK1070806
|
6 weeks
|
|
Comparison of downstream Th1 cytokines
Time Frame: 6 weeks
|
Including interferon gamma, IP-10, IL-10, IL-2, IL-1β and TNF.
Pre and post GSK1070806.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Rona M Smith, MD MRCP, Cambridge University Hospitals NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Behcet1070806
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.